Development of optimal infusion regimens for epoprostenol using radio labelled platelet uptake over atherosclerotic lesions in man

1. Epoprostenol (prostacyclin, PGI2) has been evaluated in clinical trials in peripheral vascular disease and other conditions chiefly on the basis of its platelet inhibitory properties. These therapeutic evaluations have proceeded in the absence of evidence as to the optimum infusion regimen for ep...

Ausführliche Beschreibung